Published in J Card Fail on December 23, 2008
Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol (2013) 1.23
Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail (2009) 0.97
Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease. Heart Fail Clin (2012) 0.87
The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail (2015) 0.85
Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design. Syst Rev (2013) 0.84
Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int (2014) 0.78
Pharmacologic management of chronic reno-cardiac syndrome. Curr Heart Fail Rep (2013) 0.77
A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure. Clin Med Insights Cardiol (2016) 0.75
Response to Sexton: Inhibiting the renin-angiotensin-aldosterone system in patients with heart failure and renal dysfunction: common sense or nonsense? Circ Heart Fail (2014) 0.75
Development and validation of algorithms for heart failure patient care: a Delphi study. Singapore Med J (2015) 0.75
Effectiveness of β-blockers in heart failure with left ventricular systolic dysfunction and chronic kidney disease. J Card Fail (2013) 0.75
Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. J Geriatr Cardiol (2016) 0.75
Short-term outcomes after hospital discharge in patients admitted with heart failure in Abeokuta, Nigeria: data from the Abeokuta Heart Failure Registry. Cardiovasc J Afr (2014) 0.75
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J (2017) 0.75
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med (2007) 18.45
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med (2004) 17.91
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet (2005) 9.00
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Bariatric surgery and long-term cardiovascular events. JAMA (2012) 7.11
Glycemic control and excess mortality in type 1 diabetes. N Engl J Med (2014) 6.39
Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med (2012) 6.19
Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature (2013) 6.07
Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension (2007) 5.61
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Atenolol in hypertension: is it a wise choice? Lancet (2004) 4.75
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA (2004) 3.68
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet (2004) 3.59
Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A (2010) 3.51
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 3.40
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol (2009) 3.32
Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med (2015) 3.20
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol (2009) 3.14
Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med (2004) 2.98
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification. Am J Gastroenterol (2013) 2.95
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 2.90
Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun (2012) 2.84
Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens (2003) 2.72
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J (2008) 2.65
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care (2005) 2.59
Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.36
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure. Eur J Heart Fail (2004) 2.30
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol (2004) 2.26
Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens (2003) 2.24
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol (2009) 2.19
Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. J Am Coll Cardiol (2011) 2.19
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J (2007) 2.17
Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA (2008) 2.09
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med (2003) 2.09
Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol (2013) 2.08
Implications of geographical variation on clinical outcomes of cardiovascular trials. Am Heart J (2012) 2.06
Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol (2007) 2.05
What are the odds at ASCOT today? Lancet (2003) 2.02
Can the relation between tooth loss and chronic disease be explained by socio-economic status? A 24-year follow-up from the population study of women in Gothenburg, Sweden. Eur J Epidemiol (2005) 1.96
Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens (2007) 1.96
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. Nephrol Dial Transplant (2005) 1.94
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol (2010) 1.94
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood (2011) 1.93
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J (2012) 1.93
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol (2004) 1.88
Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene (2004) 1.83
Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol (2007) 1.75
Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation (2002) 1.74
Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol (2005) 1.71
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA (2012) 1.71
Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J (2009) 1.71
Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J (2005) 1.71
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation (2002) 1.63
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens (2008) 1.61
Right ventricular pacing and the risk of heart failure in implantable cardioverter-defibrillator patients. Heart Rhythm (2006) 1.60
Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. Europace (2006) 1.60
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J (2006) 1.58
Atrial ultrastructural changes during experimental atrial tachycardia depend on high ventricular rate. J Cardiovasc Electrophysiol (2004) 1.57
A family with Andersen-Tawil syndrome and dilated cardiomyopathy. Heart Rhythm (2006) 1.56
Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med (2005) 1.54
The prognosis for individuals on disability retirement. An 18-year mortality follow-up study of 6887 men and women sampled from the general population. BMC Public Health (2006) 1.54
Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J (2004) 1.54
Tuberculosis in Bissau: incidence and risk factors in an urban community in sub-Saharan Africa. Int J Epidemiol (2004) 1.54
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension (2004) 1.52
The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol (2011) 1.51
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 1.51
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens (2002) 1.51
Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart (2010) 1.50